Join to View Full Profile
200 UCLA Medical Plz Ste 450Los Angeles, CA 90095
Phone+1 310-825-6911
Fax+1 310-794-7005
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 1 invite waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Roger Lo, MD is a dermatologist in Los Angeles, California. He is currently licensed to practice medicine in California. He is an Assistant Professor of Dermatology at UCLA.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Dermatology, 2003 - 2007
Westchester Medical CenterInternship, Internal Medicine, 2002 - 2003
Weill Cornell MedicineClass of 2002
Certifications & Licensure
CA State Medical License 2003 - 2025
National Board of Physicians and Surgeons Dermatology
Publications & Presentations
PubMed
- 7 citationsThe Fanconi anemia pathway induces chromothripsis and ecDNA-driven cancer drug resistance.Justin L Engel, Xiao Zhang, Mingming Wu, Yan Wang, Jose Espejo Valle-Inclán
Cell. 2024-10-17 - 2 citationsPerspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy).Paolo A Ascierto, Sanjiv S Agarwala, Allison Betof Warner, Marc S Ernstoff, Bernard A Fox
Journal of Translational Medicine. 2023-07-28 - 14 citationsMulti-organ landscape of therapy-resistant melanoma.Sixue Liu, Prashanthi Dharanipragada, Shirley H Lomeli, Yan Wang, Xiao Zhang
Nature Medicine. 2023-05-01
Press Mentions
Dr. Roger Lo Awarded NIH Grant to Tackle Melanoma Treatment ResistanceSeptember 24th, 2024- “Rapid Autopsies” Offer New Perspective of Melanoma ProgressionMay 3rd, 2023
- Researchers Study Genetic Changes in Tumors of Recently Deceased Patients with MelanomaMay 2nd, 2023
- Join now to see all
Grant Support
- Melanoma Resistance Evolution Atlas (MREA) for identifying combinatorial targets to prevent and reverse MAPKi resistanceUNIVERSITY OF CALIFORNIA LOS ANGELES2024–2029
- Melanoma Resistance Evolution Atlas (MREA) for identifying combinatorial targets to prevent and reverse MAPKi resistanceUNIVERSITY OF CALIFORNIA LOS ANGELES2024–2029
- Melanoma Resistance Evolution Atlas (MREA) for identifying combinatorial targets to prevent and reverse MAPKi resistanceUNIVERSITY OF CALIFORNIA LOS ANGELES2024–2029
- Preventing MAPK inhibitor resistance in melanoma by targeting genomic instability and immune resistanceUNIVERSITY OF CALIFORNIA LOS ANGELES2013–2029
- Preventing MAPK inhibitor resistance in melanoma by targeting genomic instability and immune resistanceUNIVERSITY OF CALIFORNIA LOS ANGELES2013–2029
- Preventing MAPK inhibitor resistance in melanoma by targeting genomic instability and immune resistanceUNIVERSITY OF CALIFORNIA LOS ANGELES2013–2029
